1. Home
  2. RDIB vs MDWD Comparison

RDIB vs MDWD Comparison

Compare RDIB & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RDIB

Reading International Inc Class B

BUY

Current Price

$11.95

Market Cap

256.7M

ML Signal

BUY

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$17.00

Market Cap

224.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDIB
MDWD
Founded
1937
2000
Country
US
Employees
N/A
N/A
Industry
Movies/Entertainment
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
256.7M
224.6M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
RDIB
MDWD
Price
$11.95
$17.00
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$37.50
AVG Volume (30 Days)
24.7K
97.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$6.97
Revenue Next Year
$13.42
$23.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.81
$14.14
52 Week High
$17.40
$22.51

Technical Indicators

Market Signals
Indicator
RDIB
MDWD
Relative Strength Index (RSI) 50.54 43.41
Support Level $9.23 $16.97
Resistance Level $12.83 $17.91
Average True Range (ATR) 1.69 0.70
MACD -0.00 -0.03
Stochastic Oscillator 34.09 8.38

Price Performance

Historical Comparison
RDIB
MDWD

About RDIB Reading International Inc Class B

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: